The submission also covers the LumiraDx swab kit. Credit: Mufid Majnun on Unsplash.

LumiraDx has announced a 510(k) dual submission to the US Food and Drug Administration (FDA) seeking approval for its five-minute COVID Ultra Test.

The application has been submitted for LumiraDx SARS-CoV-2 Ag Ultra with CLIA Waiver to commercially supply the LumiraDx Platform, including the LumiraDx instrument along with the LumiraDx SARS-CoV-2 Antigen (Ag) Ultra test.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

This submission also covers the LumiraDx SARS-CoV-2 Ag Quality Control Swab Kit.

The LumiraDx SARS-CoV-2 Ag Ultra Test utilises the company’s advanced technology for identifying the SARS-CoV-2 presence.

It is designed to provide accurate results and is already marketed in Europe and several global markets.

LumiraDx Clinical Regulatory and Quality Global SVP Carol Adiletto-Francis said: “LumiraDx remains committed to delivering innovative diagnostic solutions that address critical healthcare needs.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“The submission of this first 510(k) application represents a significant milestone in the company’s journey towards receiving FDA approval for the COVID Ultra Test.

“This also forms the foundation for additional submissions of other high-performing assays on the same platform, many of which are available in Europe and elsewhere and others which are in late stages of development.”

During the pandemic, the company secured various Emergency Use Authorizations (EUA) for its SARS-CoV-2 Ag tests.

In February this year, LumiraDx received the FDA EUA and the UK Health Security Agency (UKHSA) validation for a multiplex test for Covid-19 and influenza A and B.

Named LumiraDx SARS-CoV-2 and Flu A/B STAR Complete, the assay enables laboratories to rapidly detect and differentiate individuals with respiratory viral infections consistent with Covid-19.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact